An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-Reactive CD4⁺ T Cell Responses in Seronegative Volunteers

• Published in: Clinical infectious diseases Vol. 52; no. 4; pp. 522 - 531
• Main Authors: Van Braeckel, Eva, Bourguignon, Patricia, Koutsoukos, Marguerite, Clement, Frédéric, Janssens, Michel, Carletti, Isabelle, Collard, Alix, Demoitié, Marie-Ange, Voss, Gerald, Leroux-Roels, Geert, McNally, Lisa
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 15.02.2011
• Subjects: Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - adverse effects; Adolescent; Adult; AIDS Vaccines - adverse effects; AIDS Vaccines - immunology; Antibodies; Antigens; Biological and medical sciences; CD4-Positive T-Lymphocytes - immunology; Clinical medicine; Cytokines; Cytokines - biosynthesis; Dosage; Female; HIV; HIV 1; HIV Infections - immunology; HIV Infections - prevention & control; HIV Seronegativity - immunology; HIV-1 - immunology; HIV/AIDS; Human immunodeficiency virus; Human immunodeficiency virus 1; Human viral diseases; Humans; Immune response; Immunization, Secondary - methods; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infections; Infectious diseases; Male; Medical research; Medical sciences; Proteins; Recombinant Fusion Proteins - immunology; T cell receptors; T lymphocytes; Tumor necrosis factors; Vaccination; Vaccination - methods; Vaccines; Vaccines, Subunit - adverse effects; Vaccines, Subunit - immunology; Vaccines, Synthetic - immunology; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Young Adult; Human; Immunopathology; HIV-1 virus; Volunteer; Retroviridae; AIDS; Vaccine; Immune deficiency; Lentivirus; Infection; Virus; Prevention; Immunoprophylaxis; Immunological investigation; Viral disease; T-Lymphocyte; Cross reaction; Human immunodeficiency virus

Background. This phase I/II partially blinded, randomized, dose-ranging study assessed the safety and immunogenicity of a novel human immunodeficiency virus type 1 (HIV-1) vaccine candidate consisting of a recombinant fusion protein (F4) containing 4 HIV-1 clade B antigens (Gag p24, Pol reverse tran...